Thinking ahead: The need for early diagnosis and treatment in a broad spectrum of CKD
IMPORTANCE
In order to apply for CME credits, Omnihealth Practice will collect your professional details and participation results for the corresponding College/ CME Programmes Administrator.
PLEASE ENSURE YOUR ACCOUNT DETAILS ARE CORRECT, including full name, and registration number. Omnihealth Practice is not responsible for any failure on application due to error details provided by participant. Should you have any questions, please contact [email protected]
To receive a certificate, you must achieve a passing score as designated by the corresponding college/ CME Programmes Administrator. You may view or print the certificate from RECORD, but you cannot alter it.
All the CME accredited programmes on Omnihealth Practice Education Portal are approved for healthcare professionals in Hong Kong SAR ONLY.
CME released:
9 December 2024
Valid for credit through:
8 December 2025
CME accredited by:
9 December 2024 - 8 February 2024
TBC
CRMSynced Forum is a professional, integrated educational platform for Hong Kong healthcare professionals to receive the latest updates on international guidelines for cardio-renal-metabolic disease and related information, such as case reports, insightful articles and lectures. The platform includes interviews with numerous key opinion leaders (KOLs) in the field, from whom local healthcare professionals can gain valuable insights.
About the programme
Professor Christoph Wanner highlights the alarming prevalence of undiagnosed CKD, especially among patients with cardiovascular conditions, where traditional screening primarily focuses on the estimated glomerular filtration rate (eGFR). He emphasizes the need to include urine albumin-creatinine ratio (uACR) testing for early diagnosis. The EMPA-KIDNEY trial showcases the efficacy of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, in slowing eGFR decline across diverse CKD populations, including frail individuals. Prof. Wanner advocates for the adoption of updated KDIGO guidelines recommending SGLT2 inhibitors, including empagliflozin, for CKD management, which can enhance patient outcomes and quality of life. By emphasizing early detection and comprehensive assessments, he aims to address therapeutic gaps in CKD treatment and improve healthcare practices globally.
This is an independent editorial article, published and distributed through unrestricted educational support from the pharmaceutical community, for the purpose of continuing medical education only. The views expressed in this publication reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher, and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on editorial content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.